A Multicenter, Double-Blind, Flexible-Dose, 6-Month Trial Comparing the Efficacy and Safety of Asenapine With Olanzapine in Stable Subjects With Predominant, Persistent Negative Symptoms of Schizophrenia.

Trial Profile

A Multicenter, Double-Blind, Flexible-Dose, 6-Month Trial Comparing the Efficacy and Safety of Asenapine With Olanzapine in Stable Subjects With Predominant, Persistent Negative Symptoms of Schizophrenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 May 2017

At a glance

  • Drugs Asenapine (Primary) ; Olanzapine
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms APHRODITE
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 22 Dec 2011 Primary endpoint 'Positive-and-Negative-Syndrome-Scale' has not been met.
    • 17 Jan 2008 Status changed from recruiting to completed.
    • 30 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top